Major US Market Opportunity For Petscreen Canine Cancer Programme
18 years ago
3750 views
Posted
26th January, 2006 00h00
The unveiling of a unique canine cancer screening, detection and treatment programme at the largest International Veterinary Conference in the world, has proved to be a significant success.
Launched by an innovative British bioscience company at the North American Veterinary Conference (NAVC) in Orlando, Florida, the Petscreen Veterinary Cancer Programme (www.pet-screen.com) attracted much attention from the veterinary community in the United States and around the world. In addition, key US market partners expressed serious interest in taking up the programme to make it widely available in the US.
Petscreen’s founding partners, Professor Graeme Radcliffe and Dr Kevin Slater are sufficiently confident that an announcement will be made at this year’s British Small Animals Veterinary association (April 20th-23rd, 2006, National Indoor Arena, Birmingham, UK).
Canine cancer is at the top of the veterinary professions agenda across the world. In some breeds cancer is endemic…. And since the recent sequencing of the dog genome, there has been an active drive to join up initiatives which will help to detect, and treat cancer at a very early stage. The American Kennel Club, The Morris Animal Foundation and a host of senior animal oncologists have now flagged canine cancer as having one of their foremost areas of attention.
The programme developed by Petscreen is the first of its kind and will enable very early detection of canine cancer from a blood ‘fingerprint’.
The screening service is based on proteomic technology, which looks for characteristic patterns to detect a range of cancer markers in serum samples. The technology enables malignancies to be picked up early when treatment has the best chance of success. It is inexpensive, convenient and minimally invasive, making it ideal for regular yearly or bi-annual testing in high risk canine breeds.
If cancer is detected a combined rapid histopathology and individualized chemotherapy service is uniquely available. Petscreen’s Directed Chemotherapy Assay (DCA) highlights resistance from the start, and identifies the treatments most likely to be effective. This impact of the chemotherapy treatment on tumour regression can then be monitored by further proteomic sampling.
The programme will be available through selected veterinary hospitals and primary practices across the UK…….and many practices have expressed interest in adopting the Petscreen programme.
Petscreen has launched their Preferred Partner programnme in the UK and USA to rapidly fast track the availability of the service during 2006. Already potential Market partners in Europe and Japan have approached the company………and they hope to shortly announce a global partnership with a large international corporation, to enable them to globalize their operations very quickly.
Petscreen is one of a new generation of companies to utilize technologies which are emerging as a result of genome research. Headquartered in Biocity, Nottingham, one of the UK’s leading centres of bioscience excellence, Petscreen will work with forward thinking veterinary hospitals and practices in an effort to widely provide positive detection and treatment of this devastating disease.
“Using innovative technologies and data analysis to shine light into dark places is the consummate focus of the Petscreen group,” comments Professor Graeme Radcliffe, company chairman. “Playing a global role to focus, support and help not one but many dogs (and cats very soon) is our absolute passion and commitment!”
More from
